title: Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
abstract: BACKGROUND
  LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM) and/or high TG. These levels are lowered by extended-release niacin (ERN), and changes in the ratios of these levels may affect ASCVD risk. This analysis examined the effects of extended-release niacin/laropiprant (ERN/LRPT) on the relationships between apoB:LDL-C and apoB:non-HDL-C in patients with T2DM.
  
  
  METHODS
  T2DM patients (n = 796) had LDL-C ≥1.55 and <2.97 mmol/L and TG <5.65 mmol/L following a 4-week, lipid-modifying run-in (~78 % taking statins). ApoB:LDL-C and apoB:non-HDL-C correlations were assessed after randomized (4:3), double-blind ERN/LRPT or placebo for 12 weeks. Pearson correlation coefficients between apoB:LDL-C and apoB:non-HDL-C were computed and simple linear regression models were fitted for apoB:LDL-C and apoB:non-HDL-C at baseline and Week 12, and the correlations between measured apoB and measured vs predicted values of LDL-C and non-HDL-C were studied.
  
  
  RESULTS
  LDL-C and especially non-HDL-C were well correlated with apoB at baseline, and treatment with ERN/LRPT increased these correlations, especially between LDL-C and apoB. Despite the tighter correlations, many patients who achieved non-HDL-C goal, and especially LDL-C goal, remained above apoB goal. There was a trend towards greater increases in these correlations in the higher TG subgroup, non-significant possibly due to the small number of subjects.
  
  
  CONCLUSIONS
  ERN/LRPT treatment increased association of apoB with LDL-C and non-HDL-C in patients with T2DM. Lowering LDL-C, non-HDL-C and apoB with niacin has the potential to reduce coronary risk in patients with T2DM.
authors.affiliation: Division of Atherometabolic Research, Utah Foundation for Biomedical Research, 420 Chipeta Way, Room 1160, Salt Lake City, UT, 84108, USA. eliot.brinton@utah.edu.
authors.forename: Eliot A
authors.initials: EA
authors.lastname: Brinton
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Triscari
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Brudi
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Erluo
authors.initials: E
authors.lastname: Chen
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Amy O
authors.initials: AO
authors.lastname: Johnson-Levonas
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Christine McCrary
authors.initials: CM
authors.lastname: Sisk
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Rae Ann
authors.initials: RA
authors.lastname: Ruck
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Alexandra A
authors.initials: AA
authors.lastname: MacLean
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Darbie
authors.initials: D
authors.lastname: Maccubbin
authors.affiliation: Merck & Co., Inc., Kenilworth, NJ, USA.
authors.forename: Yale B
authors.initials: YB
authors.lastname: Mitchel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053299:Apolipoprotein B-100 / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: C569471:APOB protein, human; D053299:Apolipoprotein B-100; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007211:Indoles; D007328:Insulin; C518174:MK-0524; D014280:Triglycerides; D009525:Niacin
keywords: ApoB; Extended-release niacin/laropiprant; LDL-C and non-HDL-C; Type 2 diabetes mellitus